Femasys Inc 8-K, filed Jun 15, 2023
Femasys Inc (FEMY)
8-K
2023-06-15
For: 2023-06-14
View Original
Added on
April 06, 2026
About this 8-K
Femasys Inc filed this 8-K on June 15, 2023, reporting on events of June 14, 2023.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 14, 2023
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
(770 ) 500-3910
(Registrant’s telephone number, including area code)
n/a
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instructions A.2. below):
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Exchange Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each
exchange
on which registered
|
||
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
| Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
|
Effective June 14, 2023, the Board of Directors of Femasys Inc. (the “Company”) accepted John Dyett and John Adams’s resignation from the Board of
Directors. Messrs. Dyett and Adams’s resignations did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. In connection with Messrs. Dyett and Adams’s resignations, the Board of
Directors appointed Keith J. Kendall and Alistair Milnes as directors of the Company. There are no arrangements or understandings between Messrs. Kendall and Milnes and any other persons pursuant to which Messrs. Kendall and Milnes were elected as
directors of the Company. Messrs. Kendall and Milnes will be entitled to the applicable annual retainer and equity awards pursuant to the Company’s director compensation policy, under terms consistent with those previously disclosed by the Company.
Messrs. Kendall and Milnes will also be entitled to enter into an indemnification agreement with the Company. Mr. Kendall will hold office as a Class III director for a term expiring at the annual meeting following the year ending December 31, 2023
and will serve as Chairperson on the Audit Committee of the Company. Mr. Milnes will hold office as a Class I director for a term expiring at the annual meeting following the year ending December 31, 2024 and will serve on the Audit Committee and
Nominating and Corporate Governance Committees of the Company. In addition, effective June 14, 2023, Anne Morrisey, a current member of the Board of Directors, resigned from serving on the Audit Committee.
Mr. Kendall has served as Founder Partner and Chief Executive Officer at KSquared Strategic Advisors since June 2022, which provides strategic, corporate
development and capital markets advisory services. Previously, he served as Chief Executive Office and President of Aquestive Therapeutics, a commercial-stage pharmaceutical company, from November 2014 to May 2022, and previously served as their
Chief Operating Officer from November 2011 to November 2014, and Executive Vice President and Chief Financial Officer from 2006 to 2011. Mr. Kendall had previously served in various business leadership positions for Hewlett Packard Financial
Services, including as Vice President and Managing Director of the Americas and held a number of positions with AT&T Capital Corporation, including President of AT&T Credit Corporation and NCR Credit Corporation. Mr. Kendall received his B.S.
from St. John’s University and an M.B.A from Pace University. The Board of Directors believes that Mr. Kendall is qualified to serve on our board of directors due to his experience as a life sciences executive, as well as his leadership and operating
experience.
Mr. Milnes has served as Chief Operating Officer at Bicycle Therapeutics, a clinical-stage biopharmaceutical company, since January 2022 and previously
served as Vice President, Human Resources and Communications from January 2021 to December 2021. Previously, he provided independent human resources consulting services from October 2020 to December 2020, and also served as Strategic Advisor at Rio
Tinto with a focus on transformation, people and communications from January 2020 to December 2020, and in roles of increasing responsibility at Gazprom Marketing & Trading Ltd., from 2010 to October 2019, including serving as Director of Global
Human Resources and Communications, from December 2017 to October 2019 and Director of Global Human Resources from 2013 to November 2017. Mr. Milnes received his B.A. from Edinburgh Napier University. The Board of Directors believes that Mr. Milnes
is qualified to serve on our board of directors due to his experience as a biotechnology executive, as well as his leadership experience in expediting company growth and market expansion.
| Item 8.01 |
Other Events
|
On June 15, 2023, the Company issued a press release announcing the appointment of Messrs. Kendall and Milnes as members of the Company’s Board of
Directors. A copy of the press release is being filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 9.01 |
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits
|
|
Exhibit
No.
|
Description
|
|
Press Release of Femasys Inc. dated June 15, 2023.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Femasys Inc.
|
||
|
By:
|
/s/ Kathy Lee-Sepsick
|
|
|
Names: Kathy Lee-Sepsick
|
||
|
Title: Chief Executive Officer
|
||
|
Date: June 15, 2023
|
||
Exhibit 99.1
Femasys Inc. Replaces Two Board Members with Seasoned Industry Leaders in the Life Sciences
-- Keith Kendall former President, COO and CFO of drug delivery company, Aquestive Therapeutics and Alistair Milnes COO of
biotechnology company, Bicycle Therapeutics both join Femasys’ Board of Directors –
ATLANTA, June 15, 2023 – Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include
minimally invasive, in-office technologies for reproductive health, today announced that it has appointed Mr. Keith J. Kendall and Mr. Alistair Milnes to its board of directors. Messrs.
Kendall and Milnes will be replacing Mr. John Dyett, who currently serves as Co-CEO of Salem Partners, LLC and Salem Partners Wealth Management, LLC and Mr. John Adams, formerly served as CEO and President of Adams Respiratory Therapeutics, who
both have served as members of Femasys’ board of directors for over eight years. Mr. Kendall will also replace Mr. Dyett as Audit Committee Chair.
Ms. Kathy Lee-Sepsick, founder, president and chief executive officer of Femasys, commented, “We are excited to welcome Keith Kendall and Alistair Milnes to our board. Both
serve as a great fit with our existing board due to their very expansive experience as life sciences executives, which will be invaluable as we continue to expand our commercial portfolio of novel
biomedical solutions available to women worldwide. Mr. Kendall brings decades of leadership and financial and operating experience. Mr. Milnes’ experience as a biotechnology executive includes
leadership experience in expediting company growth and market expansion. We are immensely thankful to John Dyett and John Adams for their long-standing service with the Company, with John Dyett being instrumental in his support and guidance for our
IPO and financings and John Adams offering operating insight from our time as a private company to becoming a public company.”
Keith J. Kendall serves as Founder and Chief Executive Officer at KSquared Strategic Advisors, a firm that provides strategic, corporate development and capital markets
advisory services. Previously, he served as Chief Executive Officer and President of Aquestive Therapeutics, a commercial-stage, biopharmaceutical drug delivery company and prior to that served as their Chief Operating Officer and Chief Financial
Officer. Mr. Kendall has served in various business leadership positions for blue-chip companies such as Hewlett Packard Financial Services, including serving the role of Vice President and Managing Director of the Americas, and held a number of
positions with AT&T Capital Corporation, including President of AT&T Credit Corporation and NCR Credit Corporation.
Mr. Kendall received his B.S. from St. John’s University and an M.B.A from Pace University.
Mr. Kendall commented, “I look forward to working together with Femasys’ management in support of the mission to change women’s health at this crucial time of the
Company’s development, as well as leading the audit committee, following multiple product approvals and with key potential approvals on the horizon.”
Alistair Milnes serves as Chief Operating Officer at Bicycle Therapeutics, a clinical-stage biopharmaceutical company, and previously served as Vice
President, Human Resources and Communications there. Previously, he provided independent human resources consulting services, and also served as a Strategic Advisor at Rio Tinto with a focus on transformation, people and communications, and in roles
of increasing responsibility at Gazprom Marketing & Trading Ltd., including serving as Director of Global Human Resources and Communications.
Mr. Milnes received his B.A. from Edinburgh Napier University.
Mr. Milnes, commented, “I am thrilled to join Femasys’ board of directors at this exciting time of growth for the Company. I look forward to applying
my expertise to the Company’s next phase of growth as the Company becomes more established in its commercial stage of development.”
About Femasys
Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of products and product candidates that include minimally invasive,
in-office technologies for reproductive health. Its two lead product candidates are FemBloc® permanent birth control and FemaSeed® localized directional insemination for infertility. The Company’s products currently marketed
in the United States include FemVue® for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath®, an intrauterine catheter for selective evaluation of
the fallopian tubes, and FemCerv®, an endocervical tissue sampler that is the first product of the technology platform for tissue sampling. To learn more, visit www.femasys.com
or follow us on Twitter, Facebook, and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be
identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could
cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include,
among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our
product candidates and other positive results; estimates regarding the total addressable market for our product candidates; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and
those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022 and other reports as filed with the SEC. Forward-looking statements contained in this press
release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
Investors
Chuck Padala
LifeSci Advisors, LLC
917-741-7792
chuck@lifesciadvisors.com
Femasys Inc.
Investor Contact:
IR@femasys.com
Media Contact:
Media@femasys.com